Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
551. |
ECCT/18/12/02 | Randomized Controlled Trial to Compare the Effect of Corn-Soy Blend + Vegetable Oil 8 and Fish Oil (CSB-VO-FO) With Corn-Soy Blend + Vegetable Oil Alone (CSB-VO) on 9 the Immunological and Microbiota Patterns among Children Aged 6 to 24 months with 10 Mod Randomized Controlled Trial to Compare the Effect of Corn-Soy Blend + Vegetable Oil 8 and Fish Oil (CSB-VO-FO) With Corn-Soy Blend + Vegetable Oil Alone (CSB-VO) on 9 the Immunological and Microbiota Patterns among Children Aged 6 to 24 months with 10 Mod |
Principal Investigator(s) 1. CHRISTOPHER L. MELBY MELBY Site(s) in Kenya KENYA MEDICAL RESEARCH INSTITUTE |
25-02-2019 |
View |
552. |
ECCT/14/04/01 | REACH Trial REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANAEMIA. |
Principal Investigator(s) 1. Thomas Neil Williams Site(s) in Kenya Kilifi County Hospital |
07-07-2014 |
View |
553. |
ECCT/12/09/02 | Reduction of EArly mortaLITY in adults and children Reduction of EArly mortaLITY in HIVinfected adults and children starting antiretroviral therapy (REALITY) |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Wellcome Trust Research Programme (Kilifi county) |
04-04-2012 |
View |
554. |
ECCT/16/12/02 | Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial. |
Principal Investigator(s) 1. ISAAC TSIKHUTSU Site(s) in Kenya KEMRI/WRP, KERICHO |
10-01-2017 |
View |
555. |
ECCT/22/05/03 | Anti-malaria MAb in Kenyan chi Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in an Age De-Escalation, Dose-Escalation Trial and a Randomized, Placebo-Controlled, Double-Blind Trial of Children in Western Kenya |
Principal Investigator(s) 1. Titus Kwambai 2. Laura Steinhardt 3. Robert A Seder Site(s) in Kenya 1. Siaya County Referral Hospital (Siaya county) 2. Kogelo Health Center (Siaya county) |
08-08-2022 |
View |
556. |
ECCT/23/04/02 | Shigella 53G study in Kenya Safety and feasibility of a Shigella sonnei 53G controlled human infection model in Kenyan adults: a dose finding and dose verification study |
Principal Investigator(s) 1. Melissa Kapulu 2. Fredrick Sawe Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
21-08-2024 |
View |
557. |
ECCT/19/08/01 | Use of malaria infection by injection to study malaria transmission Safety and feasibility of a malaria transmission model in semi-immune Kenyan adults using Plasmodium falciparum sporozoites |
Principal Investigator(s) 1. Melissa Kapulu 2. Philip Bejon Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
15-11-2019 |
View |
558. |
ECCT/19/04/01 | A study to determine if a new shigella vaccine (Shigella4V) is safe, induces immunity and the best dose among Kenyan infants. Safety and immunogenicity of a Shigella-tetravalent bioconjugate vaccine: A phase 1/2 randomized controlled and age descending study including dose finding in 9-month-old infants |
Principal Investigator(s) 1. Mainga Hamaluba 2. Kosgei Josphat Site(s) in Kenya 1. KEMRI-United States Army Medical Research Unit-Kenya, Kericho (Kericho county) 2. KEMRI Wellcome Trust Research Program-CGMR-C (Kilifi county) |
08-07-2019 |
View |
559. |
ECCT/09/09/02 | MAL-58 Study: Protocol no. 112745: SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS\' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN |
Principal Investigator(s) 1. LUCAS OTIENO TINA 2. MARY HAMEL Site(s) in Kenya 1. KEMRI-CDC, (Siaya county) 2. KEMRI-WRP (Kisumu county) |
24-06-2010 |
View |
560. |
ECCT/20/06/01 | IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults |
Principal Investigator(s) 1. Prof Walter Jaoko Godfrey Jaoko Site(s) in Kenya 1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county) |
02-12-2020 |
View |